Micron Biomedical lands $4.5 million NIAID contract to counter radiation injury with a microneedle patch

PartnershipxempritolimodPositive

AI Analysis

Summary

Micron Biomedical secured a $4.5 million NIAID contract to develop a microneedle patch combining its dissolvable microarray technology with Connext's xempritolimod for treating Acute Radiation Syndrome. The project is part of NIAID's Radiation and Nuclear Countermeasures Program announced on July 27, 2026.

Outcome Details

$4.5 million NIAID contract for development of medical countermeasure against radiation injury

Importance:5/10

Sentiment:

0.70

government fundingmicroneedle deliveryradiation injurymedical countermeasurepartnership

Related Companies

$NHC

Read the original article

Published by Drug Discovery & Development on August 4, 2026 8:08 PM

Read Original